AstraZeneca Pharma India Limited receives import and market permission for Dapagliflozin Tablets 10mg

AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg.

Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m2).

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.3895.1 as compared to the previous close of Rs. 3848.25. The total number of shares traded during the day was 6833 in over 1554 trades.

The stock hit an intraday high of Rs. 3943.25 and intraday low of 3871. The net turnover during the day was Rs. 26690915.

Source : Equity Bulls

Keywords